European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

MT Newswires Live10-14

European equities traded in the US as American depositary receipts were marginally lower late Wednesday morning, declining 0.04% to 1,880.82 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and Grifols (GRFS), which advanced 3.4% and 1.8% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and medical device maker EDAP TMS (FOCL), which increased 1.4% and 1.2% respectively.

The decliners from continental Europe were led by accommodations booking site trivago (TRVG) and internet browser company Opera (OPRA), which fell 2.4% and 1.8% respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and Banco Santander (SAN), which were down 1.6% and 1.5% respectively.

The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company AstraZeneca (AZN), which climbed 26% and 3.6% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company GSK (GSK), which rose 2.8% and 2.7% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which lost 8.2% and 5.6% respectively. They were followed by mining company BHP Group (BHP) and lender HSBC (HSBC), which dropped 2.3% and 1.6% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment